BAF312 (Siponimod) is a potent sphingosine-1 receptor (S1P-R) modulator selectively targeting S1P1 and S1P5 receptors [1]. BAF312 reduces inflammation by sequestering lymphocytes in lymphoid tissues [2]. BAF312 also binds its receptors on neurons, astrocytes and oligodendrocytes and present neuroprotective effects [3]. Siponimod showed neuroprotective effects in the CNS of encephalomyelitis mice and organotypic cultures. is currently under investigation in a clinical trial in secondary progressive multiple sclerosis patients [4].

BAF312 (Siponimod) is a potent sphingosine-1 receptor (S1P-R) modulator selectively targeting S1P1 and S1P5 receptors [1]. BAF312 reduces inflammation by sequestering lymphocytes in lymphoid tissues [2]. BAF312 also binds its receptors on neurons, astrocytes and oligodendrocytes and present neuroprotective effects [3]. Siponimod showed neuroprotective effects in the CNS of encephalomyelitis mice and organotypic cultures. is currently under investigation in a clinical trial in secondary progressive multiple sclerosis patients [4].